Abstract
INTRODUCTION
The concept of patient-prosthesis mismatch (PPM) was first described in 1978 by Rahimtoola [1] . It occurs when the effective orifice area (EOA) of the prosthesis implanted is too small in relation to the patient's body surface area (BSA) [2] . The haemodynamic consequence consists of an exponential bioprosthetic transvalvular gradient increase, higher than expected. As described by Dumesnil and Pibarot, the epitome of this phenomenon would be 'the insertion of a mouse's valve into the elephant's aorta' [3] . Several studies reported a prevalence of moderate PPM following aortic valve replacements (AVRs) between 20% and 70%, whereas severe PPM ranges from 2 to 11% [4] . Discrepancies have been reported about the outcome of PPM, basically depending on the different definition of mismatch adopted.
However, it has already been demonstrated that PPM delays the regression of the left ventricle (LV) hypertrophy after surgery, as well as it is an independent predictor of mortality and cardiac events [3, 5] . To prevent PPM, many authors suggest the intraoperative evaluation of the projected EOA for every single patient, to be incorporated in the clinical decision making process along with age, physical activity, LV function and concomitant procedures. If the risk of PPM is considerable, an alternative technique should be taken into consideraton. Aortic root enlargement, homografts and stentless bioprosthesis were possible options to avoid PPM [6, 7] . However, these procedures are technically complex, require longer learning period and are associated with protracted aortic cross-clamp time (XCT). The innovative Perceval bioprosthesis (Sorin Group S.p.A., Saluggia, Italy) is a surgical sutureless self-expanding valve without a sewing ring. It has recently been introduced as an alternative to conventional surgery to minimize the operative risk in elderly patients. Advantages consist of both shortening the cardiopulmonary bypass (CPB) time and enhancing the minimally invasive †Presented at the 30th Annual Meeting of the European Association of CardioThoracic Surgery, Barcelona, Spain, 1-5 October 2016. approach [8, 9] . It also provides excellent haemodynamic results and adequate EOAs, especially in small roots, becoming a possible solution for PPM avoidance.
The aim of our study is to compare the incidence of PPM in patients undergoing a Perceval sutureless aortic valve replacement (SU-AVR) or a conventional AVR with a sutured bioprosthesis using an exact statistical matching.
MATERIALS AND METHODS

Patient population
This is an observational retrospective multicentre study examining 65 patients with severe symptomatic aortic stenosis who, between May 2012 and March 2016, underwent a SU-AVR with the Perceval bioprosthesis in 2 centres (44 + 21 patients). Moreover, 177 AVR with conventional sutured bioprosthesis were performed between August 2003 and September 2015 in the same centres (131 + 46 patients). Perceval and sutured patients were 1:1 exactly matched for sex and BSA, resulting in 62 homogeneous couples. The rationale of choosing only these 2 variables for matching consists of their impact on the aortic annulus dimensions: other parameters like age (in our adult population of biological prosthesis) and ejection fraction may potentially influence the effect of PPM on postoperative outcomes and should be considered for multivariate analysis. However, that analysis is not the objective of this study and, as a matter of fact, such variables like age and ejection fraction do not affect the valve size. Among the conventional AVR patients (n = 62), the sutured bioprosthesis adopted were: Carpentier-Edwards Magna (n = 3), Carpentier-Edwards Perimount (n = 7), Carpentier-Edwards Standard (n = 15), Medtronic Hancock II (n = 3), Medtronic Mosaic (n = 9), Sorin Mitroflow (n = 20), St. Jude Epic (n = 3), St. Jude Trifecta (n = 2).
Postoperative echocardiography was recorded before hospital discharge.
Perceval sutureless valve
The innovative sutureless Perceval bioprosthesis consists of a double sheet bovine pericardium fixed on a nitinol stent (alloy of nickel and titanium) which supports strong deformation and can return to its original shape when the stressor is removed. The stent is made of 2 rings (outflow ring and inflow ring), connected by 9 struts: 6 sinusoidal and 3 straight commissural ones. It is necessary to support the valve and hold it in place within the aortic root. A thin layer of Carbofilm TM improves biocompatibility. The super-elastic alloy allows the adaption of the device to the anatomy of the aorta. As reported by Della Barbera et al. [10] , the valve's atraumatic collapsing system does not affect the integrity of the device's leaflets.
Sutureless surgical technique
In the SU-AVRs population, a partial upper sternotomy (J-sternotomy) in the third/fourth intercostal space or a full median sternotomy was performed to obtain access to the aorta, according to the surgeon's preference. After systemic heparinization, a standard CPB was performed, cannulating the aorta, the right atrium and using a vent into the right superior pulmonary vein. After cross-clamping and cardioplegia delivery, a transverse aortotomy was performed 1 cm distal to the sinotubular junction to avoid the device interference during the closure of the aortotomy. The native valve was removed and the annulus decalcified. The sizing of the annulus was performed using the designed Perceval sizer. The Perceval valve is available in 4 sizes: size S, to be implanted in annuli from 19 to 21 mm; size M, to be implanted in annuli from 21 to 23 mm; size L, for patients with annuli of 23 to 25 mm; and size XL, for diameters from 25 to 27 mm. Three 3-0 Prolene guiding sutures were positioned 2 mm below the nadir of each native leaflet insertion line and then passed through the prosthesis' button hole to obtain a perfect alignment of the device. The valve was loaded onto a holder through a collapsing system and then deployed into the aortic root. A post-dilation with a balloon catheter at 4 Atm for 30 s and the instillation of warm saline solution guarantee the perfect positioning of the device. The guiding sutures are then removed and the aorta is closed in the usual fashion (Prolene 5-0). The crossclamp and the CPB are finally dismissed. Perceval implants were performed by 3 trained surgeons. In the sutured group, patients underwent a conventional AVR through a full sternotomy access. For the statistical analysis, we used the projected in vitro EOA for Perceval valve (Table 1 ) and the projected in vivo EOA for sutured bioprosthesis provided by the manufacturers or published in literature (Table 2 ) [11] [12] [13] [14] . For the sutureless bioprosthesis, each size covers a range of 2 annular diameters, therefore the EOA reported by Sorin varies from 2.07 to 2.20 cm 2 for the S size; from 2.47 to 2.63 cm 2 for the M size; from 2.81 to 2.95 cm 2 for L size and from 3.11 to 3.43 for the XL size. In the sutureless bioprosthesis, the in vitro EOA is provided as a range (min-max), therefore, for a more convincing analysis, the minimum value was used if the sutured valve size of the couple referred to the lowest value, while the maximum Perceval EOA was chosen to compare sutured prosthesis with the highest size of the range (i.e. for Perceval size M, which covers annulus size range 21-23 mm 
Definition of patient-prosthesis mismatch
Statistical analysis
Continuous variables were reported as mean ± SD or median and [Q1-Q3], for normally and not normally distributed data, respectively. Categorical variables were expressed as absolute and relative frequencies (%). For continuous variables, the normality of distribution was assessed with the Kolmogorov-Smirnov test. Differences between groups were calculated using a paired student t-test and a Wilcoxon signed-rank test where appropriate. Categorical variables were analysed using the Fisher and v 2 tests. P-values < 0.05 were considered significant. Statistical analysis was performed using SAS 9.3 (SAS Institute, Cary, NC, USA).
RESULTS
Patients' characteristics
Patients' characteristics before matching are provided in Supplementary material. After 1:1 pairing, the mean ± SD BSA was 1.77 ± 0.16 m 2 and 1.77 ± 0.15 m 2 in the sutureless and sutured group, respectively. In both groups, female patients were 62.9% (P = 1.00). Patients' ages were similar between groups (sutureless: 79 [75-82] years vs sutured: 79 [76-81] years; P = 0.80). No statistically significant differences were found analysing obesity (27.4% vs 19.4%; P = 0.36), coronary artery disease (35.5% vs 35.5%; P = 0.83), chronic kidney disease (27.4% vs 12.9 %; P = 0.06), chronic obstructive pulmonary disease (21.0% vs 14. 5%, P = 0.42), diabetes (19.4% vs 14.5%; P = 0.55) and polyvascular disease (17.7% vs 16.1%; P = 0.91). In the sutureless group, 27 patients (43.5%) were admitted with a III-IV New York Heart Association functional class, while in the sutured one they were 38 (61.3%; P = 0.021). Median Logistic EuroSCORE I was 8.5% [6. Preoperative patients' characteristics are summarized in Table 3 .
Intraoperative data
A minimally invasive access (III-IV intercostal space J-sternotomy) was adopted in 40 patients (64.5%) of the sutureless group (Table 4) . In all the patients who received a conventional sutured bioprosthesis, a full median sternotomy approach was performed. A concomitant coronary artery bypass graft was required in 12 (19.4%) and 18 (29.0%) subjects of the sutureless and sutured group, respectively (P = 0.16). The CPB time and XCT were significantly higher in the sutured group 
Postoperative results
Postoperative transthoracic echocardiograms show a reduction of the transvalvular mean gradients (sutureless: 13.9 ± 4.8 vs sutured: 15.0 ± 7.6 mmHg; P = 0.72) and peak gradients (sutureless: 23.2 ± 8.2 vs sutured: 18.6 ± 10.8 mmHg; P = 0.25) in both groups. After surgery, a single case of moderate central aortic regurgitation occured among the sutureless patients (P = 0.37). No cases of paravalvular leak were reported (Table 5) . A surgical revision for bleeding was necessary in 3 sutureless (4.8%) and 4 sutured (6.5%) patients (P = 0.71). No significant differences were registered analysing the rate of blood unit transfusion (sutureless: 0 [0-2] vs sutured: 1.5 [0-3]; P = 0.12) and stroke (sutureless: 1.6% vs sutured: 4.8%; P = 0.36). Three subjects who received a Perceval prosthesis (4.8%) and 18 patients who received a sutured valve (29.0%) developed an acute kidney injury during the hospital stay (P < 0.001). The duration of total postoperative hospital stay (sutureless: 6.5 [5] [6] [7] [8] vs sutured: 6 [5] [6] [7] [8] days; P = 0.58) and the intensive care unit (ICU) stay (sutureless: 1 [1-2] vs 1 [1] [2] [3] days; P = 0.57) did not differ among groups. The rate of in-hospital deaths was 1.6% and 11.3% for the sutureless and sutured groups, respectively (P = 0.30). 
GENERAL ADULT CARDIAC
Patient-prosthesis mismatch rate
After matching, the implanted valve sizes were 24 [22] [23] [24] mm and 21 [21] [22] [23] mm in the sutureless and the sutured group respectively (P = 0.002; Table 6 ). The Perceval group showed an EOA of 2.65 ± 0.28 cm 2 , while it dropped to 1.44 ± 0.35 cm 2 in the sutured patients (P < 0.001). When indexed for BSA, the indexed effective orifice area was 1.50 ± 0.18 cm 2 /m 2 and 0.81 ± 0.19 cm 2 /m 2 in the sutureless and the sutured group, respectively, with a significant statistical difference of P < 0.001 ( Figure  1 ). No PPM occurred in patients who received a Perceval bioprosthesis (n = 62, P < 0.001). In the sutured group (n = 62), 38 patients (61.3%) developed a PPM, which was moderate in 41.9% (n = 26) and severe in 19.4% (n = 12).
DISCUSSION
In this retrospective multicentre observational study, we presented 62 couples 1:1 matched for sex and BSA, selected from our populations of 65 SU-AVRs and 177 AVRs. The idea of a sutureless valve prosthesis was first described by Magovern and Cromie in 1962 [15] . The Perceval bioprosthesis does not need to be sutured; therefore it can be rapidly deployed with the consequent reduction of CPB time and XCT, minimizing the patients' risk [8, 9] . As expected, our study confirmed the reduction in the surgical times (CPB: P = 0.003 and XCT: P < 0.001). However, the advantages of the innovative sutureless bioprosthesis seem to go far beyond. It has no sewing ring and provides large EOAs. In accordance with another recently published study focusing on small annuli [16] , our results confirm Perceval's higher indexed EOA and reduced risk of PPM development, when compared with conventional sutured bioprosthesis.
A recent meta-analysis reported that moderate PPM occurs in 34.2% of the 27 186 AVRs considered, while severe in 9.8% and is associated with 1.2 and 1.8-fold increase in the risk of all-cause mortality, respectively [17] . For other authors the PPM rate could reach 70% of the conventional AVRs, a value which is comparable to our 61.3% rate of PPM in the sutured group. Several studies have failed to demonstrate the negative clinical impact of PPM on the patients' outcome. A possible explanation could be the use of different methods to estimate the PPM, leading to contradictory results. However, the majority of the authors agree that PPM consequences include: higher transvalvular gradients, a reduction of the cardiac index, a delay in the regression of LV hypertrophy after surgery, a worsening of the New York Heart Association functional class and augmented morbidity [3, 5] . PPM is also an independent predictor of early-, mid-and long-term mortality after surgery [18] [19] [20] . Tasca et al. [20] showed that PPM is an independent predictor of cardiac events (cardiac deaths, sudden deaths, heart failure, syncope/lipothymia, angina) with a 3.2-fold increased risk. Even if no precise guidelines for PPM management are present, a possible approach to treat PPM has been described by Pibarot et al.: patients with indexed effective orifice area < _0.65 cm 2 /m 2 should be considered for reintervention; while in case of indexed effective orifice area < _0.85 cm 2 /m 2 , a more close follow-up is recommended. To prevent PPM, the projected indexed EOA should be calculated at the time of surgery considering the patient's BSA and incorporating it in the clinical decision making process considering age, physical activity, LV function and concomitant procedures as well [3] . Some authors also encouraged the manufacturers of the prosthesis to provide user-friendly charts for a simple preoperative PPM prevention [21] . If the risk of PPM is considerable, an alternative strategy should be considered. Aortic enlargement procedures, homografts and different suture techniques have been extensively adopted, but they can be surgically demanding, require a longer learning period and are associated with protracted aortic XCT [6] [7] . Other alternatives to avoid PPM were mechanical and biological supra-annular valves. However, the risk of bleeding and the introduction of new attractive techonolgies were determinant in the exploration of new options. Stentless bioprosthesis represented a major advance for the better haemodynamic perfomance, but the technically demanding procedure, along with the longer surgical times, reduced its possible application. It has been shown that transcatheter aortic valve implantation improves the indexed EOA. Nevertheless, the PARTNER trial reported higher rates of paravalvular leakage, an independent predictor of mortality [22, 23] . In addition, the lack of resection and decalcification of the native valve could have an impact on the complete expansion and, as a consequence, on the EOA of the transcatheter heart valves.
For the statistical analysis, we used the projected in vivo/ in vitro EOAs values provided by the manufacturers or published in the literature. Bleiziffer et al. [24] reported that the best method for predicting PPM consists of the in vivo echocardiographic examinations, whereas the use of in vitro data and geometric orifice area is unreliable and overestimate it by 10-15%. Nonetheless, there has been relatively few data published in literature about the in vivo Perceval EOAs, and they are based on a small number of patients, with a relatively short follow-up. As a matter of fact, in the immediate intraoperative/postoperative period, considering the haemodynamic variability due to the surgical catecholamine stress and volume load, the use of the 
Limitations
The relatively small number of patients is a major drawback of our analysis. This is an observational retrospective study not of randomized design; therefore no recognized bias could occur. The definition of PPM adopted is the most commonly used, however other cut-offs might produce different results. In the same way, the application of different EOAs references for the sutured bioprosthesis might conduct to other outcomes. The use of 8 different types of sutured valves in the AVR group could be considered as a possible limitation because each valve has a different design and EOAs. On the other hand, it confirms the largest Perceval areas compared to various sutured valves considered. Perceval implantations were performed by 2 trained surgeons in 1 centre, while another single specialist realized the sutureless operations in the other one, but the implantation techniques did not differ. Furthermore, many different surgeons performed the sutured AVRs and this may have influenced the results. In the sutured group, the Logistic EuroSCORE I and mortality rates were higher, as they were chosen from a population of high surgical risk patients which, nowadays, may also be suitable for transcatheter aortic valve implantation. It is a well-known fact that there is no correspondence among the sizes of different sutured valves, in fact the numerical prosthetic diameter is not standardized. On the other hand, Perceval uses letters because each size covers precisely a range of 2 mm of annular diameter.
The length of our follow-up was not sufficient to demonstrate LV mass regression and freedom from cardiac events. A longer follow-up of the patients included in this study is therefore necessary to determine other clinical outcome differences among groups. However, the impact of PPM on the patient's outcome has already been well described in literature.
CONCLUSION
In conclusion, the indexed EOA of the sutureless group was significantly larger than in the sutured one. The incidence of PPM with the conventional sutured bioprosthesis was 61.3%, while it decreased to 0% in the sutureless group. Therefore, the Perceval sutureless valve provides larger EOAs compared to the sutured conventional bioprosthesis and could be considered as a good option to reduce the risk of a PPM.
SUPPLEMENTARY MATERIAL
Supplementary material is available at EJCTS online.
